China’s National Medical Products Administration issued final implementation measures for drug trial data protection, moving the country closer to alignment with international pharmaceutical IP standards. The policy establishes final rules governing how protected clinical trial data can be used by others, tightening expectations around confidentiality and reliance. The release marks a meaningful step for global developers and Chinese innovators planning product cycles that depend on trial investment protection. In practice, data protection rules can influence the timing and strategy for differentiation, life-cycle management, and parallel submissions. For multinational biotech, the updated measures may affect partnership terms and regulatory planning, particularly for novel modalities where clinical development costs are high and competitive entry timelines matter. The finalization also signals continued evolution of China’s regulatory approach to drug IP and market access, which can shift how deals are structured between domestic and global companies.